sarcomatoid renal cell carcinoma (Cancer)
Information
- Disease name
- sarcomatoid renal cell carcinoma
- Disease ID
- DOID:4473
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03055013 | Active, not recruiting | Phase 3 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | April 28, 2017 | June 9, 2031 |
| NCT01767636 | Active, not recruiting | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | May 16, 2013 | November 16, 2024 |
| NCT02496208 | Active, not recruiting | Phase 1 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | July 22, 2015 | September 30, 2024 |
| NCT03793166 | Active, not recruiting | Phase 3 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | June 7, 2019 | September 15, 2024 |
| NCT04272034 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | March 26, 2021 | June 20, 2026 |
| NCT03541902 | Active, not recruiting | Phase 2 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | May 15, 2018 | July 31, 2025 |
| NCT00126503 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | May 2005 | February 2012 |
| NCT06447103 | Not yet recruiting | Phase 2 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | June 1, 2024 | June 1, 2030 |
| NCT05808608 | Not yet recruiting | Phase 1/Phase 2 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | September 2023 | December 2025 |
| NCT06049576 | Recruiting | Phase 1 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | October 6, 2023 | March 14, 2026 |
| NCT03866382 | Recruiting | Phase 2 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | May 13, 2019 | February 28, 2025 |
| NCT03685448 | Unknown status | Phase 2 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) | April 11, 2019 | April 30, 2024 |
| NCT03177239 | Unknown status | Phase 2 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | October 19, 2017 | December 31, 2022 |
- Disase is a (Disease Ontology)
- DOID:4450
- Cross Reference ID (Disease Ontology)
- MESH:D002292
- Cross Reference ID (Disease Ontology)
- NCI:C27893
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128668003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1266043
- Exact Synonym (Disease Ontology)
- renal cell carcinoma, spindle cell